Based on assessments of ropeginterferon alpha-2b in a real-world setting, researchers highlighted the safety, tolerance, and efficacy of the treatment in Philadelphia-negative myeloproliferative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results